Fig. 1: Isolation and characterization of VH1-2-derived mAbs with average-length CDRL3 that target the CD4bs. | Nature Communications

Fig. 1: Isolation and characterization of VH1-2-derived mAbs with average-length CDRL3 that target the CD4bs.

From: Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein

Fig. 1

a Longitudinal serum neutralization (serum dilution that inhibits 50% of viral infectivity (ID50)) of donor H18877 against a multiclade virus panel. The geometric mean is represented as a blue line. Serum samples were obtained at 3.2, 7.5, 9.8, 12.3, 18.8, 25.0, 31.2, 34.9, 52.8 months post SC, while PBMCs were isolated at month 24.0 and 36.0 post SC as indicated by the black arrows. b Pie-chart of VH gene usage of isolated B cells from months 24 and 36 post SC (n = 222). Each gray-color coded slice represents a certain VH gene and the slice size is proportional with the amount of BCRs derived from this particular VH gene. BCRs using the VH1-2*02 gene are colored in blue. c Sequence characteristics of ACS101, ACS102 and ACS103 that use the VH1-2*02 and VL2-23*02 gene segments in their HC and LC, respectively. Somatic hypermutation (SHM) is depicted as the number of amino acid (aa) and nucleotide (nucl) mutations compared to the VH1-2*02 and VL2-23*02 germline genes. d Binding of ACS101, ACS102, ACS103, and VRC01 to AMC009 SOSIP using biolayer interferometry. e Negative stain electron microscopy 3D reconstructions of ACS101, ACS102, and ACS103 in complex with AMC009 SOSIP. Fabs were segmented, colored and are shown relative to a reference trimer for visualization and comparison. VRC01 (EMD-8269) Fab was included for comparison purposes.

Back to article page